Home / Business and Economy / Vertex Acquires Crinetics for $10B
Vertex Acquires Crinetics for $10B
7 Jul
Summary
- Vertex Pharmaceuticals is acquiring Crinetics for $10 billion.
- Crinetics develops treatments for endocrine diseases like acromegaly.
- The deal is expected to add $5 billion in annual revenue for Vertex.
Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for approximately $10 billion, a deal valued at $85 per share in cash. This significant acquisition is poised to bolster Vertex's drug development pipeline and is projected to contribute as much as $5 billion in annual revenue.
Crinetics focuses on creating treatments for endocrine diseases, which involve hormones and glands. Their key product, PALSONIFY, addresses acromegaly, a disorder causing excessive growth. The company also has other pipeline drugs for conditions like congenital adrenal hyperplasia.
Vertex, renowned for its cystic fibrosis medications, is expanding its therapeutic reach with this acquisition. The company anticipates the deal will be accretive to its operating income by 2029. Vertex plans to finance the transaction using existing cash reserves and debt.
The deal, expected to close in the third quarter, is one of the largest in the biotech sector this year, drawing comparisons to other major industry acquisitions. Retail investor sentiment on Stocktwits saw a notable shift towards Crinetics following the announcement, while Vertex maintained strong bullish sentiment.
